



Erratum

To cite this article: (2012) Erratum, Expert Opinion on Pharmacotherapy, 13:5, 781-781, DOI: [10.1517/14656566.2012.671594](https://doi.org/10.1517/14656566.2012.671594)

To link to this article: <https://doi.org/10.1517/14656566.2012.671594>



Published online: 10 Mar 2012.



Submit your article to this journal [↗](#)



Article views: 331



View related articles [↗](#)

In the article, “Optimizing treatment for patients with metastatic renal cell carcinoma in the central and Eastern European region,” by Vrdoljak, Ciuleanu, Kharkevich et al. (*Expert Opin. Pharmacother* 2012;13(02):159-74), some errors were identified. In table six, under the column Bevacizumab, in the row for Czech Republic, “100% reimbursed” should read, “100% reimbursed (reimbursed only from hospital fixed budget),” and under the column Everolimus, in the row for Czech Republic, “100% reimbursed as a second line in a specific program” should read, “100% reimbursed as a second line.”

Informa Healthcare apologises for any confusion caused.